AstraZeneca COVID Vaccination Sales Exceed Expectations, But Total Forecasts For 2022 Remain Unchanged
AstraZeneca surpassed first-quarter sales and profit projections on Friday, thanks to higher-than-expected sales of its COVID-19 vaccine, which the firm predicts will decrease sharply over the rest of the year. The vaccine generated $1.15 billion in revenues in the quarter, the majority of which came from initial contracts, but that figure above Credit Suisse’s consensus…